Groundbreaking news in the fight against HER2-positive breast cancer! A recent study published in The New England Journal of Medicine reveals significant advancements in treating advanced or metastatic HER2-positive breast cancer. This research, led by Tolaney et al., highlights the effectiveness of a new treatment combination.
What's the buzz? The study investigated a combination therapy: fam-trastuzumab deruxtecan-nxki (T-DXd) plus pertuzumab. This was compared against a standard treatment, which includes a taxane (like paclitaxel or docetaxel), trastuzumab, and pertuzumab (THP).
The Details: This international, open-label trial involved 1,157 patients. Participants were randomly assigned to one of three groups between April 2021 and October 2023. The key comparison in this interim analysis was between the T-DXd plus pertuzumab group and the THP group. Interestingly, 49% of the patients in both groups were from Asia. The primary goal was to measure progression-free survival, assessed by an independent review.
Key Findings Unveiled: At the data cutoff in February 2025, the results were striking. The median progression-free survival in the T-DXd plus pertuzumab group was 40.7 months, compared to 26.9 months in the THP group. This difference was statistically significant, with a hazard ratio of 0.56. The 24-month progression-free survival rates were 70.1% and 52.1%, respectively. The objective response rates were also higher in the T-DXd plus pertuzumab group (85.1%) compared to the THP group (78.6%).
But here's where it gets controversial... While the T-DXd combination showed superior efficacy, it's essential to consider the safety profile. Grade 3 or higher adverse events were comparable between the two groups. However, the T-DXd plus pertuzumab group showed a higher incidence of drug-related interstitial lung disease or pneumonitis (12.1%) compared to the THP group (1.0%).
In a nutshell: The researchers concluded that T-DXd plus pertuzumab significantly reduced the risk of progression or death compared to THP when used as a first-line treatment.
Important Note: The corresponding author for the New England Journal of Medicine article is Sara M. Tolaney, MD, from the Dana-Farber Cancer Institute. The study was funded by AstraZeneca and Daiichi Sankyo.
What do you think? Are you surprised by these findings? Do you have any questions about the side effects? Share your thoughts in the comments below!
